✦ LIBER ✦

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

✍ Scribed by Steven M Grunberg; Janusz Rolski; Janos Strausz; Zeba Aziz; Stephen Lane; Mark W Russo; Paul Wissel; Mary Guckert; Oliver Wright; Jørn Herrstedt

Book ID: 117785012
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 251 KB
Volume: 10
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(09)70109-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Olanzapine for the Prevention of Chemoth

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study

✍ Mizukami, Naomi; Yamauchi, Masanori; Koike, Kazuhiko; Watanabe, Akihiko; Ichihar 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 243 KB

Safety and efficacy of the novel antieme

Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial

✍ J. Herrstedt; W. Arpornwirat; I. Albert; V.L. Hansen; R.R. Bandekar; J. Levin; S 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Addition of the neurokinin 1 receptor an

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting : Results from a randomized, double-blind, placebo-controlled trial in Latin America

✍ Sergio Poli-Bigelli; Jose Rodrigues-Pereira; Alexandra D. Carides; Guoguang Juli 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

Aprepitant triple therapy for the preven

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

✍ Hu, Zhihuang; Cheng, Ying; Zhang, Hongyu; Zhou, Caicun; Han, Baohui; Zhang, Yipi 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 347 KB

The efficacy and safety of palonosetron

The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial

✍ Zhaocai Yu; Wenchao Liu; Ling Wang; Houjie Liang; Ying Huang; Xiaoming Si; Helon 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 91 KB